Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in the USA / NCT07075471
Recruiting Observational

MOVE: Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib

NCT07075471 · tracked via the Priya Life Science USA tracker
Sponsor
Deciphera Pharmaceuticals, LLC
Phase
Observational
Started
2025-09-03
Last updated
2026-07-27

Condition(s) studied

Tenosynovial Giant Cell Tumor

Study summary

The goal of this observational study is to better understand real-world use of vimseltinib, treatment patterns, and health-related quality of life in participants treated with vimseltinib for TGCT.

This study will collect data in an observational disease registry involving no intervention to the participants and will not influence standard medical care or impact treatment decisions for participants.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Diagnosis of TGCT according to medical records 2. Prescribed vimseltinib per the approved label requirements, OR The decision to receive vimseltinib has been made but treatment has not yet been initiated. 3. Has provided informed consent and medical records release Exclusion Criteria: 1\. Participant is active in an interventional clinical trial of vimseltinib

Primary outcome measure(s)

  • Duration of Vimseltinib Treatment — Baseline up to 12 months
  • Time to Discontinuation of Vimseltinib — Baseline to Discontinuation (Estimated up to 12 months)

Trial sites (1)

FacilityCityRegionStatus
Synexus Clinical Research, US INC Wilmington North Carolina Recruiting

More Deciphera Pharmaceuticals, LLC trials in the USA

Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor Active, not recruiting
A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies Active, not recruiting
A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST) Recruiting
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers Recruiting
A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD) Recruiting

Other trials for the same condition

Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor Active, not recruiting
Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER) Active, not recruiting
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor Recruiting
Study of Vimseltinib for Tenosynovial Giant Cell Tumor Active, not recruiting
A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07075471 on ClinicalTrials.gov ↗ ← All trials in the USA